Showing results (2151-2160 of 2,494) with videos related to
Sort By:
Pageof 250
ACS Applied Materials & Interfaces|February 19, 2026
Harnessing Pickering Emulsion Interfaces to Modulate Singlet Oxygen Generation for Highly Selective Oxidation of CyclohexeneHonglin Zhou, Wenxiu Yuan, Jie Dong, et al.Microbes and Infection|May 10, 2024
Absence of PD-L1 signaling hinders macrophage defense against Mycobacterium tuberculosis via upregulating STAT3/IL-6 pathwayPeijie Qu, Xinyu Li, Weihuang Liu, et al.Advanced Materials (Deerfield Beach, Fla.)|July 1, 2026
Co-Assembled Hybrid Interlayer Engineering for Enhanced Upper Interface Stability in Inverted Perovskite Solar CellsDi Lu, Junyu Wang, Yong Huang, et al.Nature Communications|January 9, 2020
TGF-β induces ST2 and programs ILC2 developmentLi Wang, Jun Tang, Xia Yang, et al.Oncotarget|September 12, 2015
MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7Jun-Tang Li, Lin-Tao Jia, Ning-Ning Liu, et al.Oncotarget|September 15, 2017
Epithelial HO-1/STAT3 affords the protection of subanesthetic isoflurane against zymosan-induced lung injury in miceLing Wang, Ya-Li Zhao, Ning-Ning Liu, et al.Oncotarget|January 20, 2017
68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patientsShiming Zang, Guoqiang Shao, Can Cui, et al.Journal of Agricultural and Food Chemistry|April 5, 2019
Functional Characterization of a Cystathionine β-Synthase Gene in Sulfur Metabolism and Pathogenicity of Aspergillus niger in Pear FruitShang-Xuan Guo, Gai-Fang Yao, Hui-Ran Ye, et al.Molecular Cancer|May 13, 2025
Profiling triple-negative breast cancer-specific super-enhancers identifies high-risk mesenchymal development subtype and BETi-Targetable vulnerabilitiesQing-Shan Chen, Rui-Zhao Cai, Yan Wang, et al.Oncotarget|May 5, 2016
Subanesthetic isoflurane relieves zymosan-induced neutrophil inflammatory response by targeting NMDA glutamate receptor and Toll-like receptor 2 signalingJun-Tang Li, Wei-Qi Wang, Ling Wang, et al.Pageof 250